Gelonghui, Feb. 21丨Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that the company is a national high-tech biomedical enterprise covering the fields of high-end preparations, biopharmaceuticals, modern traditional Chinese medicines, APIs, medical devices, biological breeding, etc. The company is rooted in the pharmaceutical industry and is based on innovation and research and development. Currently, the company's research projects include antianjil peptides, angiogenic peptides, etc. as class 1 new drugs.
赛升药业(300485.SZ)：在研项目属于1类新药的有安替安吉肽、血管生成抑肽等
Saisheng Pharmaceutical (300485.SZ): Projects under development are class 1 new drugs such as antiangitide, angiogenic inhibitor peptides, etc.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.